相似文献
1
Evaluation of 2-thioxo-2,3,5,6,7,8-hexahydropyrimido[4,5-d]pyrimidin-4(1H)-one analogues as GAA activators.
Eur J Med Chem. 2010 May;45(5):1880-97. doi: 10.1016/j.ejmech.2010.01.027. Epub 2010 Feb 1.
2
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
J Med Chem. 2012 Sep 13;55(17):7546-59. doi: 10.1021/jm3005543. Epub 2012 Aug 17.
3
The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase.
Hum Mutat. 2009 Dec;30(12):1683-92. doi: 10.1002/humu.21121.
4
Systematic structure-activity study on potential chaperone lead compounds for acid α-glucosidase.
ChemMedChem. 2012 Nov;7(11):1943-53. doi: 10.1002/cmdc.201200309. Epub 2012 Sep 11.
5
Endoplasmic reticulum stress induces autophagy through activation of p38 MAPK in fibroblasts from Pompe disease patients carrying c.546G>T mutation.
Mol Genet Metab. 2011 Dec;104(4):566-73. doi: 10.1016/j.ymgme.2011.09.005. Epub 2011 Sep 14.
6
Enzyme enhancers for the treatment of Fabry and Pompe disease.
Mol Ther. 2015 Mar;23(3):456-64. doi: 10.1038/mt.2014.224. Epub 2014 Nov 20.
7
Carnitine is a pharmacological allosteric chaperone of the human lysosomal -glucosidase.
J Enzyme Inhib Med Chem. 2021 Dec;36(1):2068-2079. doi: 10.1080/14756366.2021.1975694.
8
Synthesis and evaluation of esterified Hsp70 agonists in cellular models of protein aggregation and folding.
Bioorg Med Chem. 2019 Jan 1;27(1):79-91. doi: 10.1016/j.bmc.2018.11.011. Epub 2018 Nov 15.
10
Discovery and hit-to-lead optimization of novel allosteric glucokinase activators.
Bioorg Med Chem Lett. 2011 Sep 15;21(18):5417-22. doi: 10.1016/j.bmcl.2011.06.128. Epub 2011 Jul 18.
引用本文的文献
1
1,6--Cyclophellitol Cyclosulfamidate Is a Bona Fide Lysosomal α-Glucosidase Stabilizer for the Treatment of Pompe Disease.
J Am Chem Soc. 2022 Aug 17;144(32):14819-14827. doi: 10.1021/jacs.2c05666. Epub 2022 Aug 2.
2
Pharmacological Chaperone Therapy for Pompe Disease.
Molecules. 2021 Nov 29;26(23):7223. doi: 10.3390/molecules26237223.
3
Carnitine is a pharmacological allosteric chaperone of the human lysosomal -glucosidase.
J Enzyme Inhib Med Chem. 2021 Dec;36(1):2068-2079. doi: 10.1080/14756366.2021.1975694.
4
Second-Generation Pharmacological Chaperones: Beyond Inhibitors.
Molecules. 2020 Jul 9;25(14):3145. doi: 10.3390/molecules25143145.
5
Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase.
J Med Chem. 2012 Jun 28;55(12):5734-48. doi: 10.1021/jm300063b. Epub 2012 Jun 8.
6
Non-iminosugar glucocerebrosidase small molecule chaperones.
Medchemcomm. 2012 Jan;3(1):56-60. doi: 10.1039/C1MD00200G. Epub 2011 Oct 24.
7
High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase.
PLoS One. 2012;7(1):e29861. doi: 10.1371/journal.pone.0029861. Epub 2012 Jan 17.
8
A high throughput glucocerebrosidase assay using the natural substrate glucosylceramide.
Anal Bioanal Chem. 2012 Jan;402(2):731-9. doi: 10.1007/s00216-011-5496-z. Epub 2011 Oct 28.
9
Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.
Assay Drug Dev Technol. 2011 Jun;9(3):213-35. doi: 10.1089/adt.2011.0370.
10
High throughput screening for inhibitors of alpha-galactosidase.
Curr Chem Genomics. 2010 Dec 3;4:67-73. doi: 10.2174/1875397301004010067.
本文引用的文献
1
Pharmacological Enhancement of Mutated α-Glucosidase Activity in Fibroblasts from Patients with Pompe Disease.
Mol Ther. 2007 Mar;15(3):508-514. doi: 10.1038/sj.mt.6300074. Epub 2016 Dec 8.
2
A new resorufin-based alpha-glucosidase assay for high-throughput screening.
Anal Biochem. 2009 Jul 1;390(1):79-84. doi: 10.1016/j.ab.2009.04.010. Epub 2009 Apr 14.
3
Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors.
FEBS J. 2007 Oct;274(19):4962-71. doi: 10.1111/j.1742-4658.2007.06041.x.
4
Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II.
Mol Genet Metab. 2007 Jan;90(1):49-57. doi: 10.1016/j.ymgme.2006.09.010. Epub 2006 Nov 13.
5
New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy.
Hum Genet. 2007 Mar;121(1):1-22. doi: 10.1007/s00439-006-0280-4. Epub 2006 Nov 7.
6
Characterization of human saposins by NMR spectroscopy.
Biochemistry. 2006 Apr 25;45(16):5206-16. doi: 10.1021/bi051944+.
7
Substituted 5,5'-diphenyl-2-thioxoimidazolidin-4-one as CB1 cannabinoid receptor ligands: synthesis and pharmacological evaluation.
J Med Chem. 2005 Apr 7;48(7):2509-17. doi: 10.1021/jm049263k.
8
Glycogenosis type II: identification and expression of three novel mutations in the acid alpha-glucosidase gene causing the infantile form of the disease.
Mol Genet Metab. 2004 Mar;81(3):203-8. doi: 10.1016/j.ymgme.2003.11.011.
9
Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II.
Hum Mutat. 2004 Jan;23(1):47-56. doi: 10.1002/humu.10286.
10
Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).
Curr Mol Med. 2002 Mar;2(2):145-66. doi: 10.2174/1566524024605789.
Zotero 插件